Phytopharm

www.phytopharm.co.uk

Symbol: PYM.L

Currently trading at: 6.25p UP 0.25

Phytopharm is focused on the research and development of novel pharmaceutical and functional food products based on clinical and pre-clinical data generated from medicinal plant extracts.

The Company has seven development programmes in four disease areas: neurodegeneration, obesity and metabolic disease, dermatology and inflammation and has a portfolio of two marketed veterinary products.

It is listed in the LSE

Staff

Contact details

Articles relating to Phytopharm

Phytopharm’s losses widen; major programmes on track

Phytopharm in the red but reports good progress; in product licensing talks

Gains across the board make August a good month for Silicon Fen’s top 20

News briefs: Phytopharm reports smooth progress; more sales for Autonomy

Cambridge Cluster pharmas tackle treatments for the bald, wrinkly, and overweight

Just five Silicon Fen high techs hold back the stock market red ink

News snippets: Phytopharm gets $1.16m from Michael J. Fox Foundation; CSR halves cost of embedded GPS

Biotech Phytopharm fights back with good news, and a broker

Briefs: CSR, Autonomy release new products: Phytopharm CEO, CFO leave; Dialight sees good progress

Phytopharm narrows losses, pleases market

Subscribe

 

Corporate profiles

 • Cambridge Biostability

Jane Whitrow Financial Director

Cambridge Biostability Ltd is a privately held company founded in 1998 with a combination of investor funding and project financing. It has a portfolio of patents and is entering into a number of agreements to licence and provide outsourced production of thermo-stable liquid vaccines and drugs. Development

[Cambridge Biostability's profile]

Top20 Index

Currently: 71.78

Business Networking Events
Check out the fascinating and informative business networking events that are coming up.

Create Publisher Site
This Publisher Website ( slot3.siliconfenbusiness.com ) does not exist in Direct-Link-Ads.com. Please create it now.